Connect your AI

Novavax NVAX Other Working Capital

Other Working Capital at other companies

ModernaMRNA

-$6M-200%

Roivant SciencesROIV

-$8.3M-230%

Viridian Therapeutics, Inc.VRDN

-$169K-2,917%

ALN

Alnylam PharmaceuticalsALNY

$2.99M+115%

ImmunityBio, Inc.IBRX

$16K-93.4%

Mirum Pharmaceuticals, Inc.MIRM

$278K-21.9%

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's other working capital?: Novavax (NVAX) reported other working capital of $8.97M in Q1 2026.
How has Novavax's other working capital changed year-over-year?: Novavax's other working capital increased by 154.2% year-over-year, from -$16.55M to $8.97M.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.